Summary of NICE guidance for Non-alcoholic fatty liver disease / Cirrhosis

Karoline Brennan, Senior Medicines Information Pharmacist, North West Medicines Information CentreSource North West Medicines Information CentrePublished

Since this edition of NICE Bites was published, the MHRA has issued restrictions and precautions on the use of fluoroquinolone antibiotics because of rare reports of disabling and potentially long-lasting or irreversible side effects (see Drug Safety Update for details). NICE is reviewing its recommendations accordingly. Please go to NICE to check for updates to this guideline.

NICE Bites is a monthly prescribing bulletin from the North West Medicines Information Centre which summarises key prescribing points from NICE guidance.  NICE Bites No 88, June/July 2016 includes two topics:

  • Non-alcoholic fatty liver disease (NICE NG49):  sections covered include; assessment and diagnosis, referral, monitoring, treatment and management.
  • Cirrhosis (NICE NG50): sections covered include assessment and diagnosis, referral, monitoring and managing complications.

(This website entry updated November 2020)

 

 

Attachments